Tags : P-III Transthyretin Cardiomyopathy (ATTR-ACT)


Pfizer Announces Tafamidis P-III Transthyretin Cardiomyopathy (ATTR-ACT) study results

Shots:             ATTR-ACT is a P-III global study with three-arms 20mg or 80mg PO QD vs PBO, including patients with variant (ATTRm), wild-type (ATTRwt), or hereditary  ATTR-ACT results (N=441): Reduced all-cause mortality (29.5% vs. 42.9%); cardiovascular-related hospitalizations (0.48 vs 0.70) showing its efficacy, safety and tolerability enhancing QoL                  In Mar’18, Japan granted SAKIGAKE designation whereas […]Read More